Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Sunday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.0 %

Shares of NYSE BTX opened at $0.21 on Friday. The stock has a market capitalization of $12.07 million, a price-to-earnings ratio of -0.09 and a beta of 4.61. The stock’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $1.82. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.